mutant + WT CFTR Cl channel potentiator

oral 300 mg BID , Ph. II in COPD and CF

from 1M cmpd cell-based HTS + opt.

J. Med. Chem., May 24, 2021

Millenium/Takeda, Cambridge, MA

The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.